Sirnaomics Ltd. · HKEX:2257
Sirnaomics — Technical Presentation (March 2022)
31 slides from Sirnaomics's technical presentation, Mar 15, 2022

Slide 1: GalAhead Platform & Programs
Sirnaomics Ltd. GalAhead™ Platform & Programs March 15, 2022 Boston 0

Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by

Slide 3: Sirnaomics: Introduction
Sirnaomics: Introduction Proprietary First RNAi Broad Technology therapeutic utility driven platforms Successful fund delivery platforms oncology success Oncology, fibrosis, ▪Proprietary algorithm for raising Proprietary PNP and First to achieve siRNA drug design Raised >$300M since medical aestheti

Slide 4: Peptide Nanoparticle (PNP) Technology: Principles
Peptide Nanoparticle (PNP) Technology: Principles PNP delivery Self-Assembled Nanoparticle • Biodegradable histidine-lysine branched polymer • Envelops and protects siRNA to facilitate delivery into the targeted tissue and cell Histidine-Lysine 80-120nm • Histidine mediated protonation to facilitate

Slide 5: Sirnaomics: Programs
Sirnaomics: Programs Delivery IND Candidate Gene Targets Indications Pre-clinical IND Phase I Phase II Phase III Rights Platform Enabling 2 in clinical isSCC US Global stage China (MRCT)2 BCC US Global STP705* TGF-β1/COX-2 PNP-IT US Liver Cancer1 (Basket) ** Global 8 in IND China (MRCT)3 enabling Li

Slide 6: GalAhead: Sirnaomics' proprietary GalNAc-siRNA platform
GalAhead™: Sirnaomics’ proprietary GalNAc-siRNA platform GalAhead™ technology incorporates multiple components mxRNA™: miniaturized single-targeting RNAi triggers muRNA™: multi-unit multi-targeting RNAi triggers NB: pronounced as in Sir Galahad, a knight of the King Arthur's Round Table and one of o

Slide 7: mxRNAs: Proposed mechanism of action (MOA)
mxRNAs™: Proposed mechanism of action (MOA) antisense antisense GalNAc adaptor Single oligo 29-33 nt long RISC RISC target mRNA cleavage 6

Slide 8: mxRNA: Remarkable activity in primary hepatocytes
mxRNA™: Remarkable activity in primary hepatocytes Sequence 1 Variant–1 Variant–2 Variant–3 IC70 = 0.47 nM IC70 = 0.64 nM IC70 = 0.85 nM Max KD = 81% Max KD = 76% Max KD = 82% Sequence 2 X84961 X84962 X84963 1.2 Variant–1 1.2 Variant–2 1.2 Variant–3 IC70 = 0.84 nM IC70 = 0.85 nM IC70 = 0.93 nM 1 1 1

Slide 9: mxRNA: Outstanding in vivo activity (single dose)
mxRNA™: Outstanding in vivo activity (single dose) Animals: mice Dose: 10 mg/kg Timepoint: 5 days Readout: TMPRSS6 mRNA Statistics: One-Way ANOVA Post-hoc analysis with Tukey’s multiple comparisons test **** = p<0.0001 8

Slide 10: mxRNA: Outstanding in vivo activity (dose response)
mxRNA™: Outstanding in vivo activity (dose response) Study Design • 1, 2 & 3 configuration for sequence 1 • Doses: 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg • N= 4 C57/Bl6 mice/group • 5 day timepoint • bDNA analysis: TMPRSS6 mRNA from liver tissues Statistics: One-Way ANOVA Post-hoc analysis with Tu

Slide 11: mxRNA: Outstanding in vivo activity (duration response)
mxRNA™: Outstanding in vivo activity (duration response) Study Design • 1, 2 & 3 configuration for sequence 1 • Dose: 3mg/kg • N= 4 C57/Bl6 mice/group • Timepoints: 3-day, 1-week, 3- week, 6-week • bDNA analysis: TMPRSS6 mRNA from liver tissues Statistics: One-Way ANOVA Post-hoc analysis with Tukey’

Slide 12: mxRNA: Potential CMC advantage
mxRNA™: Potential CMC advantage Passenger (sense strand) Design Rules Constant sequence [?] Constant sequence Guide (antisense strand) Design Rules • Synthesis one: 36 nucleotides • Synthesis two: 20 nucleotides • Annealing • Synthesis one: 31-33 nucleotides Note: 1. In November 2021, Novo Nordisk a

Slide 13: mxRNA: Potential advantage package
mxRNA™: Potential advantage package Outstanding activity Relative ease of CMC mxRNA™ Solid IP position (protection and FTO) 12

Slide 14: GalAhead Programs: March 2022
GalAhead™ Programs: March 2022 Candidate IND Drug Target Indication Bioinformatics Discovery IND Nomination Enabling STP122G Factor XI Anticoagulation/Thrombosis STP125G Non-disclosed Hypertriglyceridemia Complement Complement-mediated STP144G Factor B diseases STP135G Non-disclosed Hypercholesterol

Slide 15: STP125G (non-disclosed target)
STP125G (non-disclosed target) 14

Slide 16: Humanized liver mouse model
Humanized liver mouse model 20% mouse mouse liver 80% human human hepatocytes Source: M. Grompe and S. Strom (2013) Gastroenterology, 145:1209–1214 15

Slide 17: STP125G: Humanized liver mice study design
STP125G: Humanized liver mice study design Humanized Liver Mice Animals: • humanized mice Treatment N = 36 mice total All Groups • N = 4 per group Treatment & sample collection site: • DaVinci (MA) Test compounds: • A28(14-4)mF mxRNA • A277(12-5) mxRNA Dosing: • 10 mg/kg Day 0 Day 14 Week 6 • 30 mg/

Slide 18: STP125G: Dose response in vivo (Week 2)
STP125G: Dose response in vivo (Week 2) 160 140 Percent change as compared to control 120 (Mean +SD) 100 80 60 56% 87% 73% 87% 40 88% 90% 92% 98% 20 0 PBS A28 (14-4)mF- A28(14-4)mF-30 A277(12-5)-10 A277(12-5)-30 10 mRNA Protein 17

Slide 19: STP125G: Knockdown duration
STP125G: Knockdown duration mRNA levels in liver tissues Protein levels in plasma (ELISA) 160 160 140 140 Percent change as compared to control Percent change as compared to control 120 120 100 100 (Mean + SD) (Mean + SD) 80 80 60 60 40 40 20 20 0 0 Control A28(14-4)mF A277(12-5) Control A28(14-4)mF

Slide 20: STP144G (Complement Factor B)
STP144G (Complement Factor B) 19

Slide 21: STP144G: Non-human primates (NHP) study design
STP144G: Non-human primates (NHP) study design 20

Slide 22: Complement Factor B: Bb assay background
Complement Factor B: Bb assay background From Midler FJ et al (2007) Nat Struct & Mol Biol (14) 224–8 21

Slide 23: STP144G: Bb levels with lead compounds in NHP
STP144G: Bb levels with lead compounds in NHP Single Treatment Comparison Multiple Treatment Comparison BLQ BLQ Range Range Days Days Max reduction of Factor Bb and duration of response Max reduction of Factor Bb and duration of response • 106-13(4) • 106-13(4) ─ Max suppression of 74% at week 5 ─ M

Slide 24: STP122G (Coagulation Factor XI)
STP122G (Coagulation Factor XI) 23

Slide 25: Factor XI: Knockdown in non-human primates (NHP) study design
Factor XI: Knockdown in non-human primates (NHP) study design 24

Slide 26: Factor XI (NHP): Primary activity readout (up to week 33)
Factor XI (NHP): Primary activity readout (up to week 33) All groups Groups: 2x, 3x Group: 3x 25

Slide 27: Factor XI (NHP): Secondary activity readout and pathway specificity
Factor XI (NHP): Secondary activity readout and pathway specificity Extrinsic Pathway: Intrinsic Pathway: Prothrombin time test (PT) Activated Partial Thromboplastin Time test (APTT) The prothrombin test specifically evaluates the presence of APTT measures the integrity of the intrinsic system facto

Slide 28: Factor XI (NHP): Secondary activity readout and pathway specificity
Factor XI (NHP): Secondary activity readout and pathway specificity APTT PT • Reductions in plasma FXI activity correlated well with elevation of APTT • No effect on PT values • Dose dependent elevation of APTT 27

Slide 29: Factor XI (NHP): Safety readouts
Factor XI (NHP): Safety readouts Baseline Week 2 Week 6 Week 18 Week 26 Week 33 (pre-treatment) (2 weeks post-treatment) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) (Mean ± SD)

Slide 30: GalAhead Programs: March 2022
GalAhead™ Programs: March 2022 Candidate IND Drug Target Indication Bioinformatics Discovery IND Nomination Enabling STP122G Factor XI Anticoagulation/Thrombosis STP125G Non-disclosed Hypertriglyceridemia Complement Complement-mediated STP144G Factor B diseases STP135G Non-disclosed Hypercholesterol

Slide 31: Questions?
P- Questions? Simna@mics icing RNAi Therapeutics. 30
Source: Internet Archive copy of sirnaomics.com





